Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Rybniker

Showing results (61-70 of 111) with videos related to

Pageof 12
Sort By:
The Journal of Antimicrobial Chemotherapy|November 30, 2020
Pharmacokinetics of remdesivir in a COVID-19 patient with end-stage renal disease on intermittent haemodialysisFritz Sörgel, Jakob J Malin, Henning Hagmann, et al.
Jac-Antimicrobial Resistance|January 9, 2026
Therapeutic drug monitoring-guided treatment of XDR TB with an RpoB I491F mutation-a case reportAngela Klingmüller, Sylvia Zuber, Ada M Hoffmann, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 22, 2017
Repurposing QuantiFERON for Detection of Neutralizing Interferon-γ Autoantibodies in Patients With Nontuberculous Mycobacterial InfectionsIsabelle Suárez, Clara Lehmann, Henning Gruell, et al.
European Journal of Medicinal Chemistry|September 12, 2024
Replacement of the essential nitro group by electrophilic warheads towards nitro-free antimycobacterial benzothiazinonesHéctor Torres-Gómez, François Keiff, Peter Hortschansky, et al.
Angewandte Chemie (International Ed. in English)|November 10, 2025
Discovery and Total Synthesis of Crossiguanipyrazines with Potent Activity Against Mycobacterium tuberculosisHaowen Zhao, Etienne Bickel, Jiaqi Liu, et al.
The European Respiratory Journal|November 24, 2022
Long-term multidrug- and rifampicin-resistant tuberculosis treatment outcome by new WHO definitions in GermanyRalf Otto-Knapp, Brit Häcker, David Krieger, et al.
Cell Host & Microbe|June 7, 2015
Mycobacterium tuberculosis Differentially Activates cGAS- and Inflammasome-Dependent Intracellular Immune Responses through ESX-1Ruth Wassermann, Muhammet F Gulen, Claudia Sala, et al.
Medicine|August 16, 2021
Providing care in isolation while awaiting SARS-CoV-2 test results: Considering differential diagnoses and avoiding anchoring biasKirsten Schmidt-Hellerau, Charlotte Meyer-Schwickerath, Gregor Paul, et al.
HIV Medicine|March 8, 2023
Immune response to mRNA-based COVID-19 booster vaccination in people living with HIVJakob J Malin, Isabelle Suárez, Lena M Biehl, et al.
Cell Chemical Biology|January 5, 2024
Discovery of dual-active ethionamide boosters inhibiting the Mycobacterium tuberculosis ESX-1 secretion systemRaphael Gries, Jason Chhen, Edeltraud van Gumpel, et al.
Pageof 12

Showing results (61-70 of 111) with videos related to

Sort By:
Pageof 12
The Journal of Antimicrobial Chemotherapy|November 30, 2020
Pharmacokinetics of remdesivir in a COVID-19 patient with end-stage renal disease on intermittent haemodialysisFritz Sörgel, Jakob J Malin, Henning Hagmann, et al.
Jac-Antimicrobial Resistance|January 9, 2026
Therapeutic drug monitoring-guided treatment of XDR TB with an RpoB I491F mutation-a case reportAngela Klingmüller, Sylvia Zuber, Ada M Hoffmann, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 22, 2017
Repurposing QuantiFERON for Detection of Neutralizing Interferon-γ Autoantibodies in Patients With Nontuberculous Mycobacterial InfectionsIsabelle Suárez, Clara Lehmann, Henning Gruell, et al.
European Journal of Medicinal Chemistry|September 12, 2024
Replacement of the essential nitro group by electrophilic warheads towards nitro-free antimycobacterial benzothiazinonesHéctor Torres-Gómez, François Keiff, Peter Hortschansky, et al.
Angewandte Chemie (International Ed. in English)|November 10, 2025
Discovery and Total Synthesis of Crossiguanipyrazines with Potent Activity Against Mycobacterium tuberculosisHaowen Zhao, Etienne Bickel, Jiaqi Liu, et al.
The European Respiratory Journal|November 24, 2022
Long-term multidrug- and rifampicin-resistant tuberculosis treatment outcome by new WHO definitions in GermanyRalf Otto-Knapp, Brit Häcker, David Krieger, et al.
Cell Host & Microbe|June 7, 2015
Mycobacterium tuberculosis Differentially Activates cGAS- and Inflammasome-Dependent Intracellular Immune Responses through ESX-1Ruth Wassermann, Muhammet F Gulen, Claudia Sala, et al.
Medicine|August 16, 2021
Providing care in isolation while awaiting SARS-CoV-2 test results: Considering differential diagnoses and avoiding anchoring biasKirsten Schmidt-Hellerau, Charlotte Meyer-Schwickerath, Gregor Paul, et al.
HIV Medicine|March 8, 2023
Immune response to mRNA-based COVID-19 booster vaccination in people living with HIVJakob J Malin, Isabelle Suárez, Lena M Biehl, et al.
Cell Chemical Biology|January 5, 2024
Discovery of dual-active ethionamide boosters inhibiting the Mycobacterium tuberculosis ESX-1 secretion systemRaphael Gries, Jason Chhen, Edeltraud van Gumpel, et al.
Pageof 12